Description
(nicknamed “Reta”) is an investigational, weekly, subcutaneous injection that functions as a “triple agonist” (GIP, GLP-1, and glucagon receptor agonist). Developed by Eli Lilly, it is designed for obesity and type 2 diabetes treatment, showing potential for up to 24–28% weight reduction in trials.
Key details:
• Mechanism: Targets three receptors (GIP, GLP-1, GCG) instead of one (like semaglutide) to enhance satiety and speed up metabolism.
• Status: Not yet FDA-approved; currently in Phase 3 clinical trials, with potential availability by late 2026 or 2027.
• Results: Early trials showed significant weight loss (~24% over 48 weeks) and improved metabolic outcomes.
ryanm9708 –
Phenomenal product. Great results. If you want to cut weight fast and effectively Reta is the best choice hands down.
SCOTT DUNHAM (verified owner) –
This company is great. I was a little skeptical at first but their customer service was really helpful and knowledgeable in explaining the different peptides, they respond very fast, and most importantly the Reta is legit. I ordered it and received it the next day. I just started 9 days ago at 200lbs. I weighed myself today and im at 189lbs.
SCOTT DUNHAM (verified owner) –
Update i lost 30 lbs in 5 weeks at a very low dose, zero side affects at the lower micro dose level.